Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

A statistical note

Selection of an endpoint

Lee, Jeannette Y., Ph.D.; Blumenschein, G. R., M.D.a; Stewart, D., M.D.b; Bodey, G. P., M.D.b

American Journal of Clinical Oncology: June 1982 - Volume 5 - Issue 3 - p 261–266
Article: PDF Only
Buy

AN IMPORTANT ASPECT OF CLINICAL TRIALS is evaluating response to therapy. In studying cancer treatments, one is not only interested in whether a patient has suffered an event such as death, but also how long after treatment the event occurred. These events are also termed endpoints. In this paper, the merits and pitfalls of some commonly used endpoints are discussed and guidelines for selecting an appropriate endpoint are presented.

a Department of Medicine, Medical Breast Section, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas.

b Department of Developmental Therapeutics, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas.

© Lippincott-Raven Publishers.